Recent advances in targeted therapy have led to the development of PI3Kα inhibitors such as alpelisib and inavolisib, which have shown clinical benefit and are approved for the treatment of PIK3CA-mutated HR+/HER2− advanced BC when combined with fulvestrant (17, 18). The gene discussed is PIK3CA; the disease is breast cancer.